Drugs / ALVAC vCP1452
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00056797 | Mar 2002 → Mar 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALVAC vCP1452 | “ALVAC vCP1452 vaccine is a recombinant canarypox HIV vaccine that is administered as a monthly intramuscular injection.” NCT00056797 ↗ |
| Modality | Vaccine | “ALVAC vCP1452 vaccine is a recombinant canarypox HIV vaccine” NCT00056797 ↗ |
| Route | Intramuscular | “administered as a monthly intramuscular injection” NCT00056797 ↗ |